Concepedia

Author

Florian Huemer

Paracelsus Medical UniversityORCID

Also Known As

F Huemer, F. Huemer, FLORIAN HUEMER, Florian Huemer

78

Publications

4.3K

Citations

18

H-Index

21

Concepts

All Affiliations

Paracelsus Medical UniversityInnsbruck Medical UniversityKepler UniversitätsklinikumUniversität InnsbruckMedical University of Graz
FH

About

Florian Huemer is an author at Paracelsus Medical University specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

142

2

Pathology

3

3

71

3

Cell Biology

1

1

13

4

Neurology

1

1

11

5

Pharmacology

1

1

23

Florian Huemer

×

27

Publications

4K

Citations

16

H-Index

YearCitations

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna,

New England Journal of Medicine

2018

3.3K

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer

Florian Huemer, Gabriel Rinnerthaler, Theresa Westphal,

Oncotarget

2018

88

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade

Florian Huemer, David Lang, Theresa Westphal,

Journal of Clinical Medicine

2019

73

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Martin Reck, Rafał Dziadziuszko, Shunichi Sugawara,

Lung Cancer

2024

49

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI

Thomas Melchardt, Katharina Troppan, Clemens Hufnagl,

Journal of the National Comprehensive Cancer Network

2015

45

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini, Maximilian J. Hochmair, Hannah Fabikan,

Therapeutic Advances in Medical Oncology

2021

44

OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results

Stephen V. Liu, Rafał Dziadziuszko, Shunichi Sugawara,

Journal of Thoracic Oncology

2023

35

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM

Florian Huemer, Thomas Melchardt, Bettina Jansko,

European Journal Of Haematology

2019

26

OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy

Benjamin Besse, Mark M. Awad, Patrick M. Forde,

Journal of Thoracic Oncology

2021

23

C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients

Konstantin Schlick, Teresa Magnes, Florian Huemer,

Journal of Clinical Medicine

2019

21

Page 1